SOURCE: Lifeline Biotechnologies, Inc.

August 30, 2006 08:31 ET

Lifeline Biotechnologies, Inc. Moves Forward With Corporate Acquisition Strategy -- as Featured on MacReport.Net

RENO, NV -- (MARKET WIRE) -- August 30, 2006 -- Lifeline Biotechnologies, Inc. (www.lbtn.com) (PINKSHEETS: LBTN) today announced that Jim Holmes, CEO and President of Lifeline Biotechnologies, Inc., was featured on MacReport.Net. In his interview, Mr. Holmes updated the investment community on the future direction of the Company, as well as the updates and developments of Lifeline Biotechnologies' agreement with Solos Endoscopy, Inc. (PINKSHEETS: SLSE) for its three products (MastaScope™, First Warning System™ and the OvaScope™) that are designed to assist in the early detection of breast and ovarian cancers.

Mr. Holmes reminded shareholders of the recent stock dividend, which may be expected to be approximately 1 share of Solos Endoscopy, Inc. stock for each 100 shares of Lifeline Biotechnologies, Inc. The ratio of dividend shares to the number of shares owned will be determined, in part, by the total shares outstanding as of the record date, August 18, 2006. The stock dividend payment date is on or before September 29, 2006.

Lifeline Biotechnologies, Inc. recently announced that it received approximately 8.3 million shares of TrendSetter Industries (PINKSHEETS: TSSP) which represents more than $600,000 in total value which will be added to the company's balance sheet. The acquisition of TrendSetter is part of Lifeline's strategy to increase shareholder value by improving its asset valuation and the potential of issuing dividends to its shareholders.

"I am very excited to have this opportunity to increase shareholder awareness of our new corporate direction to the investment community. Lifeline Biotechnologies, Inc. is very confident that our corporate strategy will bring added value to our shareholders," stated Jim Holmes, CEO of Lifeline Biotechnologies, Inc.

To hear the interview in its entirety, visit http://www.macreport.net and click on "Search Interviews" on the left-hand column. Interviews require free registration, and can be accessed either by locating the respective company's ticker symbol or company name.

About MacReport.Net

The MacReport.Net is an information and media company that provides a Web-based forum for public and private issuers to communicate corporate audio and video news content to the business, financial and investing community through its Web site, located at http://www.macreport.net. The MacReport.Net also plans to provide creative and production services to develop visual events ranging from live coverage of merger announcements to public relations campaigns to new product introductions.

About Lifeline Biotechnologies, Inc.

Lifeline Biotechnologies, Inc. (www.lbtn.com) develops and acquires undervalued companies which have innovative technology in the medical, nutraceutical, and energy industries, to increase the growth of the Company. Lifeline Biotechnologies continues to seek out and capitalize on emerging technologies that will change the medical, nutraceutical, and energy community.

Statements contained in this news release, other than those identifying historical facts, constitute 'forward-looking statements' within the meaning of Section 21E of the Securities Exchange Act of 1934 and the Safe Harbor provisions as contained in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements relating to the Company's future expectations, including but not limited to revenues and earnings, technology efficacy, strategies and plans, are subject to safe harbors protection. Actual company results and performance may be materially different from any future results, performance, strategies, plans, or achievements that may be expressed or implied by any such forward-looking statements. The Company disclaims any obligation to update or revise any forward-looking statements.

Contact Information

  • Contact:
    Lifeline Biotechnologies, Inc.
    Investor Relations
    407-884-0444
    or
    1-866-THE-APPL(E)